SEC SIC 1987 3826 mapped to NACE Rev. 2 26.51 in PLEASANTON · CA · US. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for 10x Genomics, Inc. combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
10x Genomics, Inc. is a SEC SIC 1987 3826 mapped to NACE Rev. 2 26.51 based in PLEASANTON, CA, the United States.
10x Genomics, Inc. is listed in US Securities and Exchange Commission (SEC EDGAR) under registry number 0001770787. This profile consolidates official annual accounts into one indexable company dossier.
Companies in this NACE 26.51 band file annual accounts with SEC EDGAR.
Across the 2021-2025 window revenue has grown, moving from €490,490,000 to €642,823,000. EBITDA for 2025 comes in at -€24,786,000.
An indicative valuation band is available for 10x Genomics, Inc., based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2025 (period end 2025-12-31).
If you are researching 10x Genomics, Inc. for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and an indicative valuation into a single, citation-ready view.
Public regulator-filed figures across 5 years.
10x Genomics, Inc. is registered under NACE 26.51: SEC SIC 1987 3826 mapped to NACE Rev. 2 26.51. That places the business within the American cluster for this activity.
According to the company registry, 10x Genomics, Inc. is based in PLEASANTON, CA, US.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for 10x Genomics, Inc. may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| 202331 Dec 2023 | €618,727,000 | -€229,817,000 | €965,143,000 | €741,043,000 | Open PDF |
| 202231 Dec 2022 | €516,409,000 | -€142,576,000 | €1,028,980,000 | €805,743,000 | Open PDF |
| 202131 Dec 2021 | €490,490,000 | -€31,135,000 | €1,018,826,000 | €817,568,000 | Open PDF |
The most recently filed annual accounts cover fiscal year 2025 (period end 2025-12-31), publicly available via US Securities and Exchange Commission (SEC EDGAR).
